A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.

Authors

Hope S. Rugo

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Hope S. Rugo , Rui Li , Oana Petrenciuc , Amily Zhang , Robert E. Coleman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2^- hormone receptor⁺ breast cancer patients with bone metastases.

First Author: Robert E. Coleman

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2^- hormone receptor⁺ breast cancer patients (pts) with bone metastases (mets).

First Author: Robert E. Coleman

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.

First Author: Peter Schmid

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).

First Author: Mario Campone